CANY
VCYT icon

Caxton Associates (New York)’s Veracyte VCYT Stock Holding History

Caxton Associates (New York)’s Portfolio VCYT Stock Details VCYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10,298
Closed -$284K – 750
2022
Q1 		$284K Buy
+10,298
New +$295K 0.02% 372
2019
Q3 		– Sell
-16,923
Closed -$482K – 549
2019
Q2 		$482K Sell
16,923
-4,509
-21% -$113K 0.06% 198
2019
Q1 		$536K Buy
+21,432
New +$409K 0.08% 134

Other funds holding VCYT

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Caxton Associates (New York)'s VCYT Position: Q2 2022 in Review

Caxton Associates (New York) sold out of Veracyte (VCYT) in Q2 2022, closing a stake of 10,298 shares — an estimated $284K sold.

Caxton Associates (New York) first reported a position in VCYT in Q1 2019 and held it in 3 quarters. The position peaked at $536K in Q1 2019. 193 funds tracked by Wall St. Rank hold VCYT as of Q2 2022.

  • Caxton Associates (New York) reported no remaining Veracyte position as of Q2 2022 after selling out during the quarter.
  • Caxton Associates (New York) sold 10,298 Veracyte shares in Q2 2022, an estimated $284K.
  • Caxton Associates (New York) first reported a position in Veracyte in Q1 2019 and held it in 3 quarters.
  • Caxton Associates (New York)'s Veracyte position peaked at $536K in Q1 2019.
  • 193 funds tracked by Wall St. Rank held Veracyte as of Q2 2022.

Based on Caxton Associates (New York)'s 13F filing for Q2 2022, filed 15 Aug 2022.